Healthcare Analysts hold a two-part series on Alzheimer’s Disease, with the first part including Prothena on an Analyst/Industry conference call to be held on March 31.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRTA:
- Prothena says no cash deposits or securities at Silicon Valley Bank
- Prothena sees FY23 cash burn of $213-$229M
- Prothena reports Q4 EPS 12c, consensus (47c)
- TipRanks ‘Perfect 10’ List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks
- Prothena findings bode well for Phase 1 trial in AD patients, says Piper Sandler